A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study

Trial Details

NCT ID
NCT06440005
Phase
PHASE1
Sponsor
Angiex, Inc.
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • AGX101
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sarasota, Florida, United States|27.33643,-82.53065
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Histologically confirmed unresectable, locally advanced, or metastatic solid tumors.
  • Refractory to or relapsed after all standard therapies known to provide proven clinical benefit, unless the patient is not a candidate for standard…
  • Willing to authorize use of existing archival tissue, unless otherwise discussed with Sponsor
  • Time since the last dose of prior therapy to treat underlying malignancy (including other investigational therapy): Systemic cytotoxic chemotherapy…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →